To this aim, PBMC from CLL patients were cultured with or without aCD3 in the presence of DMSO, SKI-II and opaganib for 48 h and BCL-XL and MCL-1 expression was evaluated by western blot in purified viable CLL cells. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.